SG&A at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Syndax Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's SG&A?
- Syndax Pharmaceuticals (SNDX) reported SG&A of $44.92M in Q4 2025.
- How has Syndax Pharmaceuticals's SG&A changed year-over-year?
- Syndax Pharmaceuticals's SG&A increased by 48.6% year-over-year, from $30.22M to $44.92M.
- What is the long-term trend for Syndax Pharmaceuticals's SG&A?
- Over 4 years (2021 to 2025), Syndax Pharmaceuticals's SG&A has grown at a 63.3% compound annual growth rate (CAGR), from $25.24M to $179.68M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.